<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901690</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001</org_study_id>
    <nct_id>NCT03901690</nct_id>
  </id_info>
  <brief_title>Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study</brief_title>
  <acronym>BETAGENWART</acronym>
  <official_title>Betaglucin 0.2% Gel Versus Imiquimod Cream 5% in the Treatment of Anogenital Warts in 102 Individuals Older Than 18 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CALOX Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioanalisis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to determine the Efficacy of Betaglucin 0.2% in gel vs Imiquimod 5% cream in the
      treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51
      with Betaglucin 0.2% and 51 with Imiquimod 5%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Betaglucin soluble gel at 0.2% is produced in Costa Rica by a biochemical researcher.
      Obtained by chemical process improves the immune response by increasing 80 times the number
      of macrophages and Natural Killer cells. Specifically in human papillomavirus-related
      anogenital warts.

      As clinical researchers, the investigators pretend to determine the therapeutic efficacy of
      betaglucin 0.2 % gel compared with Imiquimod 5% cream in two groups of individuals from 18 to
      50 years old males and females.

      Based in mathematics and biostatistics formula used by Professor Roman Fentin, French
      academic working in the University of Costa Rica. Medicine Faculty in San Jose the number of
      participants should be 102.

      Divided into two arms. Arm betaglucin 0.2% 51 individuals treated with betaglucin soluble gel
      at 0.2% Arm imiquimod 5% 51 individuals treated with imiquimod cream at 5 % After three
      months of follow-up of all individuals, will be classified as clearance, partially cured and
      not cured.

      The plan of analysis will be:

        -  Chi-square test between the two groups (depending on the treatment) and the success or
           not of the treatment.

        -  Logistic model with a dependent variable the success or not of the treatment and with
           independent variables the treatment, sex, age. It will make it possible to verify that
           the differences observed in 1 are not due to another factor.

        -  Logistic model with a dependent variable the success or not of the treatment and with
           independent variables the treatment, the sex, the age, and an interaction sex-age. It
           will allow us to observe if there is a difference in the result according to the
           patient's sex.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective triple-blind randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>In this clinical trial, the masking is triple because neither the participants nor the researchers nor the outcomes assessor will know exactly which drug will receive.
Only through a list created mathematically by Prof R Fentin will serve as a unique guide for the administration masked either beta-glucan gel or imiquimod in cream. Both packaged in the same tube without labeling on the outside.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Completely cured will be those that present a disappearance of 80% or more of the initial volume of the wart, partially cured will be a decrease of at least 50%-79% of the initial volume of the lesion using a measurement rule applied to the larger diameter of this and not cured those that present a reduction of less than 50% of the initial volume.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Genital Wart Virus Infection</condition>
  <arm_group>
    <arm_group_label>Arm Betaglucin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Imiquimod</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>51 individuals between the ages of 18 and 50 will receive 5% imiquimod.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaglucin soluble gel 0.2%</intervention_name>
    <description>With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.</description>
    <arm_group_label>Arm Betaglucin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5% cream</intervention_name>
    <description>With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.</description>
    <arm_group_label>Arm Imiquimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 to 50 years with anogenital wart visible on physical examination
             and positive for HPV 6 and 11 by polymerase chain reaction (PCR) test with detection
             by agarose gel electrophoresis.

        Exclusion Criteria:

          -  Pregnant women.

          -  Vaccinated against human papillomavirus (Gardasil, Gardasil 9 or Cervarix).

          -  Patients Immunosuppressed by drugs (Chemotherapy, Corticoids, use of antibiotics for
             more than 7 days and/or antituberculous treatment.)

          -  Molluscum contagiosum.

          -  Skin Appendages.

          -  Urethral prolapse.

          -  Botryoid sarcoma.

          -  Herpes type II.

          -  History of anogenital surgery in the last 4 weeks.

          -  Intake of natural products or immunomodulators.

          -  Patients who have received 5% imiquimod cream.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romain Fantin, PhD. Math</last_name>
    <role>Study Chair</role>
    <affiliation>Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alejandro Perez Fabbri, OBGYN</last_name>
    <phone>+505 8626-1994</phone>
    <email>cimif.director.ejecutivo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hellen Guevara, MSC</last_name>
    <phone>+505 89988021</phone>
    <email>cimif.secretaria.ejecutiva@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica San Dominic</name>
      <address>
        <city>Managua</city>
        <zip>14027</zip>
        <country>Nicaragua</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro P Perez Fabbri, FACOG ObGyn</last_name>
      <phone>505 86261994</phone>
      <email>medicoenconsulta27@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Helen C Guevara, MSC</last_name>
      <phone>505 8998 8021</phone>
      <email>guevarad1@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Nicaragua</country>
  </location_countries>
  <reference>
    <citation>Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, Nelson A, Ault K, Trofatter KF, Liu T, Levy S, Wu J. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol. 2011;2011:806105. doi: 10.1155/2011/806105. Epub 2011 Aug 24.</citation>
    <PMID>21876641</PMID>
  </reference>
  <results_reference>
    <citation>Scardamaglia P, Carraro C, Mancino P, Stentella P. [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions]. Minerva Ginecol. 2010 Oct;62(5):389-93. Italian.</citation>
    <PMID>20938424</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri</investigator_affiliation>
    <investigator_full_name>Alejandro Pérez Fabbri MD FACOG</investigator_full_name>
    <investigator_title>Doctor in Medicine. Executive Director CIMIF</investigator_title>
  </responsible_party>
  <keyword>Betaglucin soluble gel</keyword>
  <keyword>Ano-genital warts</keyword>
  <keyword>Clearance</keyword>
  <keyword>Human papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>There is a timeline that includes a start date, end date, informed consent signature, study protocol, statistical analysis plan, informed consent form, clinical study report.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Available on May 2019 until May 2021</ipd_time_frame>
    <ipd_access_criteria>Available for clinical researchers, professors and health care providers</ipd_access_criteria>
    <ipd_url>http://cimif.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

